2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Pirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, Timo Joensuu, Ray McDermott, Petteri Hervonen, Claes Ginman, Marjaana Luukkaa, Paul Nyandoto, Akseli Hemminki, Sten Nilsson, John McCaffrey, Raija Asola, Taina Turpeenniemi-Hujanen, Fredrik Laestadius, Tiina Tasmuth, Katinka Sandberg, Maccon Keane, Ilari Lehtinen, Tiina Luukkaala, Heikki Joensuu
Institutions: Tampere University Hospital, Karolinska University Hospital, University of Helsinki, Helsinki University Hospital, Cancer Trials Ireland, University of Tampere, Karlstad Central Hospital, Turku University Hospital, Päijät-Hämeen Keskussairaala, Satakunta Central Hospital, Oulu University Hospital, Tampere University, Pirkanmaa Hospital District
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: Sanofi
OpenAlex ID: W2160129915
